BTAIQ (BioXcel Therapeutics) Other Current Payables: $0.16 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BioXcel Therapeutics Other Current Payables?

BioXcel Therapeutics BTAIQ -34.14% Other Current Payables is $0.16 Mil as of Jun. 2026. The stock has 2 warning signs investors should review.

BioXcel Therapeutics's Other Current Payables for the quarter that ended in Jun. 2026 was $0.16 Mil.

BioXcel Therapeutics's quarterly Other Current Payables increased from Dec. 2025 ($0.14 Mil) to Mar. 2026 ($0.18 Mil) but then declined from Mar. 2026 ($0.18 Mil) to Jun. 2026 ($0.16 Mil).

BioXcel Therapeutics's annual Other Current Payables declined from Dec. 2023 ($0.11 Mil) to Dec. 2024 ($0.11 Mil) but then increased from Dec. 2024 ($0.11 Mil) to Dec. 2025 ($0.14 Mil).

BioXcel Therapeutics Other Current Payables Related Terms

BioXcel Therapeutics Other Current Payables Historical Data

* Premium members only.

The historical data trend for BioXcel Therapeutics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioXcel Therapeutics Other Current Payables Chart

BioXcel Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.42 0.11 0.11 0.14

BioXcel Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.12 0.14 0.18 0.16

BioXcel Therapeutics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.16 Mil mean?
BioXcel Therapeutics (BTAIQ) has a Other Current Payables of $0.16 Mil as of Jun. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on BioXcel Therapeutics and its competitors.
Is BioXcel Therapeutics' Other Current Payables too high?
BioXcel Therapeutics' current Other Current Payables is $0.16 Mil.
How does BioXcel Therapeutics' Other Current Payables compare to YCBD and APUS?
BioXcel Therapeutics' Other Current Payables of $0.16 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on BioXcel Therapeutics and its competitors. BioXcel Therapeutics's current Other Current Payables is $0.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (BTAIQ) is currently considered Possible Value Trap. The stock's GF Value™ is $0.53, compared to a current price of $0.04 — trading 91.9% below its estimated fair value. The current Other Current Payables is $0.16 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For BioXcel Therapeutics (BTAIQ), the current Other Current Payables is $0.16 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioXcel Therapeutics Business Description

Other Exchanges BX20:Germany
Address 555 Long Wharf Drive, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.